Novartis Investigative Site
East Hanover, New Jersey, 07936-1080, United States
NCT Number: NCT00416468
This study will assess the bioavailability of aliskiren and valsartan as a single tablet compared to the same doses of the two drugs given as two separate tablets in healthy subjects.
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
East Hanover, New Jersey, 07936-1080, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
and all female subjects must have negative pregnancy results at screening and each baseline (regardless of reported reproductive status).
Exclusion criteria
Other protocol-defined inclusion/exclusion criteria may apply
Novartis
Industry
An Open-Label, Randomized, Two-Treatment, Two Period Crossover, Single-Dose Study to Determine the Relative Bioavailability of Fixed Combination of Final Market Image (FMI) Aliskiren/Valsartan 75/160 mg Tablets and the Free Combination of Aliskiren 75 mg and Valsartan 160 mg in Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06318390
Cardiovascular Diseases, Cognition Disorders
Arlington, Texas, United States
View Trial DetailsNCT05563090
Cardiovascular Diseases, Diabete Mellitus
Singapore
View Trial DetailsNCT06318377
Cardiovascular Diseases, Cognition Disorders
Arlington, Texas, United States
View Trial DetailsNCT04676152
Cardiovascular Diseases, Healthy
Irvine, California, United States
View Trial Details